Streptomycin plus PAS plus pyrazinamide in the retreatment of pulmonary tuberxulisis in East Africa.
D000293:Adolescent; D000328:Adult; D000636:Aminosalicylic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003365:Costs and Cost Analysis; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D007630:Kenya; D008297:Male; D008875:Middle Aged; D011718:Pyrazinamide / Q000008:administration & dosage* / Q000009:adverse effects; D011859:Radiography; D013183:Sputum / Q000382:microbiology; D013307:Streptomycin / Q000008:administration & dosage* / Q000009:adverse effects; D013636:Tanzania; D014397:Tuberculosis, Pulmonary / Q000000981:diagnostic imaging / Q000188:drug therapy*; D014454:Uganda
D000636:Aminosalicylic Acids; D011718:Pyrazinamide; D013307:Streptomycin